Rational Drug Design: First-in-class new drug (New Chemical Entity, NCE) development
Products currently under development are
MMP-12 inhibitors: aderamastat (FP-025) (Cardiac Sarcoidosis/sarcoidosis) and its follow-on compound linvemastat (FP-020) (asthma / inflammatory bowel disease / chronic obstructive pulmonary disease) and new series of MMP-12 inhibitors (interstitial lung diseases / neurology)
ALDH2 activator: mirivadelgat (FP-045) (pulmonary hypertension associated with interstitial lung disease) and its follow-on compounds (CVRM / neurology).
MMP-12 inhibitors
MMP-12 (matrix metalloproteinase-12/macrophage metalloelastase) is a key regulator of tissue extracellular matrix and modulator of matrikine signaling. MMP-12, a key modulator of immune and fibrotic biology, is predominantly secreted by macrophages and is becoming recognized as a key marker of inflammatory exacerbations and fibrosis. MMP-12's key role in disease is supported by genetic/GWAS evidence related to inflammatory-fibrotic diseases across multiple target tissues, namely the lung, heart and kidney.
MMP-12 Inhibitors in Chronic Immune-Fibrotic Respiratory Diseases
Modulators of Airway Remodeling and Fibrosis
ALDH2 Activators
ALDH2 (Aldehyde Dehydrogenase 2) is a mitochondrial matrix enzyme and key regulator of mitochondrial quality control systems/health and regulator of reactive aldehydes/carbonyls, oxidative stress, inflammation, and fibrosis. Activation of ALDH2 is a compelling therapeutic strategy for improving mitochondrial quality and regulatory mechanisms for the treatment of rare/orphan diseases and severe diseases of aging, including diseases of the blood, kidney, muscles, nerves/brain, lung, and heart. The key role of ALDH2 in disease is supported by strong genetic/GWAS evidence related to a dominant-negative ALDH2*2 polymorphism.
ALDH2 Activation
Unique Mitochondrial-Targeting Approach for Treatment of Multiple Diseases
